Why the Best Drug Launches Are Built to Adapt

Launching a new medicine requires a fundamentally different approach than it did even a decade ago. Patient journeys are more complex, stakeholder groups are more extensive, competition is intensifying and teams have access to more data than ever before. AI is also adding further depth and complexities to this matter as easily accessible information enables customers to become more informed and reshapes both their expectations of pharmaceutical companies and where human interaction provides value over digital engagement. At the same time, pricing, access and policy environments are changing rapidly and in unpredictable ways.

Against this backdrop, a launch strategy cannot simply be developed, approved and executed against a fixed set of assumptions. The strongest launches are increasingly designed to evolve as the market, evidence and customer needs evolve.

That means building the intelligence, governance and organizational confidence required to distinguish meaningful signals from noise and make better decisions as new evidence emerges. Rather than relying primarily on periodic reviews to identify problems after the fact, teams can increasingly understand performance as it develops, challenge assumptions earlier and intervene before issues become entrenched.

Where Traditional Approaches Fall Short

In the past, companies often adopted milestone-driven launch models when entering a market. These were built on assumptions largely fixed at the outset, such as expected access, sequencing, field deployment, stakeholder response and performance trajectory. Teams were tasked with executing the plan, and periodic reviews were scheduled to track performance.

However, companies must now account for factors such as global market volatility and higher pressure on pricing and access. These issues expose the limitations of the traditional model, which leaves a number of unmet needs. These include:

• More precise scenario planning and simulation: Instead of relying on past experience or theoretical projection, teams should be able to “pressure-test” their launch strategy with more realistic scenarios, cross-functional decision-making and clear success criteria.
• Methods of assessing functional readiness: Teams need to move beyond having a plan on paper and instead assess whether they are fully equipped to deliver on the intended strategy. This requires real-world measures of decision-making maturity and organizational confidence.
• Ability to track how decisions affect outcomes: Early choices can have an outsized effect on downstream performance and results. Teams need to quantify how resourcing, messaging and planning decisions affect performance, with evidence to support more confident decision-making.

A strategy devised at the start of a program and left untouched is not fit for purpose in the current marketplace. Instead, teams need resilient, dynamic strategies built on strong intelligence that can be quickly adapted as new information emerges.

Why Strong Foundations Still Matter Most

Emerging technologies such as AI can play a valuable role, helping teams test assumptions, identify risks early and explore different scenarios. However, technology is only as effective as the human judgment and strategy behind it. Before fine-tuning their approach to execution, companies must first develop a robust strategy that reflects market realities.

Before adding a new technology to the mix, companies need to take the time to build a shared understanding of the market and what it requires of commercial, medical and market access teams. This is the crucial element that helps build a well-defined strategy and supports everything built on top of it.

Execution Depends on Alignment

Once a defined strategy is in place, it is important to ensure that it is followed coherently throughout the development process. This is particularly important when companies are working on several different launches simultaneously.

Coordinating multiple brands, cross-functional teams and market-specific activities can lead to confusion and poor knowledge transfer if the right structures are not in place. Teams should be guided by a shared understanding of priorities and roles, with clear governance and defined decision-making processes. This empowers them to respond much more quickly to changing market conditions and emerging issues, without slowing execution.

Designing for Today’s Health Care Ecosystem

For truly effective teams, launch does not end at approval or first commercial availability. Instead, organizations should treat launches as an opportunity for continuous learning. Many factors can change after a launch, from competitor activity to prescribing behaviors. Teams can now swiftly access vital information at any point, condensed into an easily digestible format, from commercial performance data to stakeholder feedback, helping them respond rapidly and make targeted adjustments. The key is being able to confidently separate signal from noise, avoiding knee jerk reactions to every change in the market.

The focus of launch planning has also expanded beyond the initial launch. Organizations need to better understand the healthcare systems and customer journeys their product will enter, including their patients and health care professionals’ (HCPs) need and how they interact across the journey. This understanding can shape decisions around how and where teams engage, and the role of human, digital and AI-enabled interactions.

Care pathways, routes to access and the needs of different stakeholders also continue to change. Bringing these considerations into launch planning early can help teams identify potential barriers, decide where engagement will have the most impact and adjust their approach as customer needs evolve. Getting the balance right across human interaction and AI-driven tools right will be important, both in supporting the patient journey and in helping launch teams work more effectively internally across the launch.

How Technology Strengthens Execution

A focused and dynamic strategy is the core of every effective launch. It must be based on a deep understanding of clinical and commercial needs, and be adaptable if circumstances dictate. It must also be embedded early across cross-functional teams, giving each team member a clear idea of their guiding North Star.

When developing this strategy, there is no substitute for human judgment and expertise. However, technology can play a valuable role in helping teams to execute their strategy and gather insight from large amounts of available evidence.

For example, AI can accelerate launch planning through tools like LaunchNav, while also helping teams crystallize stakeholder needs, track how assets are performing in the field, and identify issues before they escalate.

Conversations between HCPs and field teams can be analyzed at scale using products like STEM AI, helping teams identify emerging trends, shift in perceptions and areas of unmet needs. These insights can inform where teams need to respond, from adapting training and coaching to reallocating resources and fine-tuning messaging. By continually feeding these insights back into execution, teams can monitor performance and make adjustments as the market evolves. This evidence can inform training and coaching needs and resource allocation, and enable teams to fine-tune messaging.

While the strategy dictates the direction and experts control decision-making, access to more detailed real-time guidance empowers teams to respond to changing dynamics and optimize their programs.

What Is the Future of Launch Excellence?

Successful launches are rarely the result of a perfect plan, executed flawlessly.They are built by teams that question assumptions and learn continuously. Technologies such as AI can help with understanding and execution, but only when supporting a robust strategy. AI-enabled decision support should be complemented by robust market validation, coordinated execution and a deep understanding of health care systems.

Today’s companies exist in an increasingly dynamic and competitive environment. This requires a new skill set: teams that are more agile, more aligned and able to make confident decisions as new information comes to light.

Ryan Wyrtzen and Mariah Hanley are partners at Inizio Ignite. Mindy McGrath is managing director and Ryan Anderson is vice president of strategic accounts.